WO2005115435A3 - Methods and compositions for control of fetal growth via modulation of relaxin - Google Patents

Methods and compositions for control of fetal growth via modulation of relaxin Download PDF

Info

Publication number
WO2005115435A3
WO2005115435A3 PCT/US2005/015248 US2005015248W WO2005115435A3 WO 2005115435 A3 WO2005115435 A3 WO 2005115435A3 US 2005015248 W US2005015248 W US 2005015248W WO 2005115435 A3 WO2005115435 A3 WO 2005115435A3
Authority
WO
WIPO (PCT)
Prior art keywords
relaxin
fetal growth
compositions
methods
control
Prior art date
Application number
PCT/US2005/015248
Other languages
French (fr)
Other versions
WO2005115435A2 (en
Inventor
Elaine Unemori
Original Assignee
Bas Medical Inc
Elaine Unemori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bas Medical Inc, Elaine Unemori filed Critical Bas Medical Inc
Priority to EP20050780049 priority Critical patent/EP1753449A4/en
Priority to AU2005247332A priority patent/AU2005247332A1/en
Priority to JP2007511088A priority patent/JP4836942B2/en
Priority to CA2563433A priority patent/CA2563433C/en
Publication of WO2005115435A2 publication Critical patent/WO2005115435A2/en
Publication of WO2005115435A3 publication Critical patent/WO2005115435A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention relates to the method for treatment, diagnosis and prevention of diseases related to fetal growth and placental insufficiency and comprises methods including inhibiting or increasing relaxin synthesis, relaxin receptor synthesis, relaxin binding to the relaxin receptor, and relaxin receptor activity. The invention also relates to screening assays to identify compounds that modulate relaxin and/or relaxin receptor activity. The invention further relates to gene therapy methods utilizing relaxin and relaxin-related sequences for the treatment and prevention of diseases related to fetal growth and placental insufficiency.
PCT/US2005/015248 2004-04-30 2005-05-02 Methods and compositions for control of fetal growth via modulation of relaxin WO2005115435A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP20050780049 EP1753449A4 (en) 2004-04-30 2005-05-02 Methods and compositions for control of fetal growth via modulation of relaxin
AU2005247332A AU2005247332A1 (en) 2004-04-30 2005-05-02 Methods and compositions for control of fetal growth via modulation of relaxin
JP2007511088A JP4836942B2 (en) 2004-04-30 2005-05-02 Methods and compositions for the control of fetal development by modulation of relaxin
CA2563433A CA2563433C (en) 2004-04-30 2005-05-02 Methods and compositions for control of fetal growth via modulation of relaxin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56735304P 2004-04-30 2004-04-30
US60/567,353 2004-04-30

Publications (2)

Publication Number Publication Date
WO2005115435A2 WO2005115435A2 (en) 2005-12-08
WO2005115435A3 true WO2005115435A3 (en) 2007-01-25

Family

ID=35451403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/015248 WO2005115435A2 (en) 2004-04-30 2005-05-02 Methods and compositions for control of fetal growth via modulation of relaxin

Country Status (6)

Country Link
US (4) US7553813B2 (en)
EP (1) EP1753449A4 (en)
JP (1) JP4836942B2 (en)
AU (1) AU2005247332A1 (en)
CA (1) CA2563433C (en)
WO (1) WO2005115435A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7878978B2 (en) 2004-03-18 2011-02-01 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Use of relaxin to increase arterial compliance
EP1729817B1 (en) * 2004-03-30 2014-03-05 Industry-Academic Cooperation Foundation Gene delivery system containing relaxin gene and pharmaceutical composition using relaxin
US7553813B2 (en) 2004-04-30 2009-06-30 Corthera, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US8496446B2 (en) * 2005-08-29 2013-07-30 Carrier Corporation Compressor muffler
US8846111B2 (en) * 2007-05-18 2014-09-30 Alltech, Inc. Compositions and methods for establishing and/or maintaining pregnancy
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
CA2717000A1 (en) * 2008-02-26 2009-09-03 Peerion Medical Technologies Ltd. Methods, systems, compositions and dosage forms for diagnosing and treating male infertility
ES2559107T3 (en) * 2008-05-16 2016-02-10 Corthera, Inc. H2 relaxin for use in the treatment of premature dilation of the cervix
WO2009149026A2 (en) * 2008-06-01 2009-12-10 Tufts Medical Center, Inc. Genomic approaches to fetal treatment and diagnosis
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
AU2009293019A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care Inc. Solute concentration measurement device and related methods
AU2013202952B2 (en) * 2008-11-24 2016-01-21 Corthera, Inc. Prediction and prevention of preeclampsia
CN102224420B (en) * 2008-11-24 2014-09-17 科尔泰拉公司 Prediction and prevention of preeclampsia
CA2753214C (en) 2009-02-27 2017-07-25 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
US9250106B2 (en) 2009-02-27 2016-02-02 Tandem Diabetes Care, Inc. Methods and devices for determination of flow reservoir volume
AU2010278894B2 (en) 2009-07-30 2014-01-30 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
WO2013033324A2 (en) 2011-08-31 2013-03-07 University Of Florida Research Foundation, Inc. Materials and methods for modulating activity of bone marrow derived cells
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US9381231B2 (en) 2012-10-09 2016-07-05 University Of Florida Research Foundation, Inc. Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9907833B2 (en) 2013-07-25 2018-03-06 University Of Florida Research Foundation, Incorporated Use of relaxin to treat placental syndromes
RU2614692C1 (en) * 2015-10-13 2017-03-28 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский институт акушерства и педиатрии" Министерства здравоохранения Российской Федерации Method for prediction of fetal growth retardation for pregnant women with placental insufficiency
DK3387019T3 (en) 2015-12-09 2022-01-10 Scripps Research Inst RELAXIN-IMMUNOGLOBULIN INFUSION PROTEINS AND METHODS OF USE
RU2663456C1 (en) * 2017-08-29 2018-08-06 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Method of diagnostics of preeclampsia on the gestation up to 34 week by evaluation of levels of ang (1-8) vasoconstrictor and ang (1-7) vasodilator
RU2674865C1 (en) * 2018-07-20 2018-12-13 Юлия Александровна Степанова Method for predicting adverse perinatal outcomes by means of complex estimation of fetus brain circulation
CN108822203A (en) * 2018-07-31 2018-11-16 杭州艾宠科技有限公司 A kind of preparation of dog relaxain recombinant protein and its monoclonal antibody
CN109136172B (en) * 2018-09-11 2022-02-11 苏州市立医院 Mouse sperm in-vitro culture kit for improving blastocyst rate and use method thereof
US10470798B1 (en) * 2018-11-30 2019-11-12 Ohana Biosciences, Inc. Methods for promoting fertilization
AU2022234737A1 (en) * 2021-03-08 2023-09-07 Research Triangle Institute Small molecule antagonists for the relaxin-3/rxfp3 system

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4109496A (en) 1977-12-20 1978-08-29 Norris Industries Trapped key mechanism
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
US4267101A (en) 1980-02-01 1981-05-12 Serono Laboratories Inc. Process for obtaining human relaxin from fetal membranes
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
ES524885A0 (en) 1982-08-12 1985-12-16 Florey Howard Inst A PROCEDURE FOR PRODUCING A DNA TRANSFER VECTOR.
US5320953A (en) 1982-08-12 1994-06-14 Howard Florey Institute Of Experimental Physiology And Medicine Process for synthesizing human H1-prorelaxin, H1-relaxin and fusion proteins thereof
US5023321A (en) 1982-12-13 1991-06-11 Howard Florey Institute Of Experimental Physiology & Medicine Molecular cloning and characterization of a further gene sequence coding for human relaxin
IL70414A (en) 1982-12-13 1991-06-10 Florey Howard Inst Polypeptide having human h2-relaxin activity,double-stranded dna fragments coding therefor,vectors containing the dna fragments and methods for preparing the polypeptide,dna fragments and vectors
US5179195A (en) 1982-12-13 1993-01-12 Howard Florey Institute Of Experimental Physiology And Medicine Human relaxin polypeptides
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3407456A1 (en) 1984-02-29 1985-09-05 Werner & Mertz Gmbh, 6500 Mainz COMBINED CLEANING / BLEACHING AGENT FOR THE TREATMENT OF THE RINSE WATER OF TOILET MACHINES AND THEIR USE
US4604590A (en) 1984-08-24 1986-08-05 Trw Inc. Microstrip circulator structure
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4835251A (en) 1986-06-23 1989-05-30 Genetech, Inc. Method of chain combination
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
WO1989002468A1 (en) 1987-09-11 1989-03-23 Whitehead Institute For Biomedical Research Transduced fibroblasts and uses therefor
ATE88352T1 (en) 1988-02-26 1993-05-15 Genentech Inc HUMAN RELAXIN PREPARATIVE.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5075217A (en) 1989-04-21 1991-12-24 Marshfield Clinic Length polymorphisms in (dC-dA)n ·(dG-dT)n sequences
JP2857684B2 (en) 1989-05-04 1999-02-17 ジェネンテク，インコーポレイテッド Methods and compositions for the isolation of human relaxin
NZ234439A (en) 1990-07-10 1997-08-22 Pharmacia & Upjohn Ab Use of igf-1 to reduce fetal growth retardation in non human mammals
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2108048T3 (en) 1990-08-29 1997-12-16 Genpharm Int PRODUCTION AND USE OF LOWER TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES.
US5364759B2 (en) 1991-01-31 1999-07-20 Baylor College Medicine Dna typing with short tandem repeat polymorphisms and identification of polymorphic short tandem repeats
US5399349A (en) 1992-02-06 1995-03-21 Paunescu; Calin Treatment of acne
WO1995003822A2 (en) 1993-07-27 1995-02-09 Mario Bigazzi Use of relaxin as therapeutic or preventing agent
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
EP0845992B1 (en) 1995-08-15 2002-11-20 Connetics Corporation Use of relaxin for promoting angiogenesis
US5972621A (en) 1995-11-27 1999-10-26 Millennium Pharmaceuticals, Inc. Methods of identifying compounds that modulate body weight using the OB receptor
US5825887A (en) * 1995-12-28 1998-10-20 Trimble Navigation Limited Transmitting and receiving apparatus for full code correlation operation under encryption for satellite positioning system
EP1253929B1 (en) 2000-02-09 2007-05-23 BAS Medical, Inc. Use of relaxin to treat diseases related to vasoconstriction
US20020123455A1 (en) * 2001-02-22 2002-09-05 Ryan Peter L. Equine relaxin as a measure of treatment efficacy
AUPR814401A0 (en) * 2001-10-08 2001-11-01 Howard Florey Institute Of Experimental Physiology And Medicine Human 3 relaxin
US7738952B2 (en) 2003-06-09 2010-06-15 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system
US7149574B2 (en) 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
AU2003903124A0 (en) 2003-06-20 2003-07-10 Mark Del Borgo Analogues of heteromeric proteins
US20050153885A1 (en) 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
ITFI20030328A1 (en) 2003-12-24 2005-06-25 Mario Bigazzi USE OF RELAXIN AS ADIUVANT IN DIFFERENTIATION
US7553813B2 (en) 2004-04-30 2009-06-30 Corthera, Inc. Methods and compositions for control of fetal growth via modulation of relaxin
US7899527B2 (en) 2004-05-13 2011-03-01 Palo Alto Investors Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
GOLDSMITH L.T. ET AL.: "Relaxin Regulation of Endometrial Structure and Function in the Rhesus Monkey", PROC. NATL. ACAD. SCI., vol. 101, no. 13, March 2004 (2004-03-01), pages 4685 - 4689, XP003006631 *
HAYES E.S. ET AL.: "Implantation and Pregnancy Following In Vitro Fertilization and the Effect of Recombinant Human Relaxin Administration in Macaca Fascicularis", BIOLOGY OF REPRODUCTION, vol. 71, no. 5, November 2004 (2004-11-01), pages 1591 - 1597, XP003006630 *
HAYES E.S. ET AL.: "Relaxin Administration During IVF/ET in Macaca Fascicularis", THERIOGENELOGY, vol. 59, no. 1, January 2003 (2003-01-01), pages 365, XP003006629 *
HAYES E.S.: "Biology of Primate Relaxin: A Paracrine Signal in Early Pregnancy", REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY, vol. 2, no. 36, June 2004 (2004-06-01), pages 1 - 22, XP003006632 *
LEE K.-Y. ET AL.: "Interleukin-6, But Not Relaxin, Predicts Outcome of Rescue Cerclage in Women With Cervical Incompetence", AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 191, no. 3, September 2004 (2004-09-01), pages 784 - 789, XP004583956 *
PETERSEN L.K. ET AL.: "Variations in Serum Relaxin (hRLX) Concentrations during Human Pregnancy", ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, vol. 74, no. 4, April 1995 (1995-04-01), pages 251 - 256, XP008074941 *
RYAN P.L. ET AL.: "Systemic Relaxin in Pregnant Pony Mares Grazed on Endophyte-Infected Fescue: Effects of Fluphenazine Treatment", THERIOGENELOGY, vol. 56, no. 3, 2001, pages 471 - 483, XP003006633 *
STEWART D.R. ET AL.: "The Relationship Between hCG and Relaxin Secretion in Normal Pregnancies vs Peri-Implantation Spontaneous Abortions", CLINICAL ENDOCRINOLOGY, vol. 38, no. 4, April 1993 (1993-04-01), pages 379 - 385, XP008074942 *
UNEMORI B. ET AL.: "Relaxin Stimulates Expression of Vascular Endothelial Growth Factor in Normal Human Endometrial Cells In Vitro and is Associated With Menometrorrhagia in Women", HUMAN REPRODUCTION, vol. 14, no. 3, March 1999 (1999-03-01), pages 800 - 806, XP003006628 *

Also Published As

Publication number Publication date
US8026215B2 (en) 2011-09-27
US20080108572A1 (en) 2008-05-08
CA2563433A1 (en) 2005-12-08
EP1753449A4 (en) 2009-09-23
US20060247163A1 (en) 2006-11-02
WO2005115435A2 (en) 2005-12-08
EP1753449A2 (en) 2007-02-21
US20060247172A1 (en) 2006-11-02
US7553813B2 (en) 2009-06-30
AU2005247332A1 (en) 2005-12-08
JP2007535574A (en) 2007-12-06
JP4836942B2 (en) 2011-12-14
CA2563433C (en) 2010-07-13
AU2005247332A2 (en) 2005-12-08
US20090318356A1 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
WO2005115435A3 (en) Methods and compositions for control of fetal growth via modulation of relaxin
WO2010021697A3 (en) Antibodies to ccr2
WO2005071080A3 (en) Modulation of glucocorticoid receptor expression
WO2007109236A8 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2008097541A3 (en) Variants derived from actriib and uses therefor
WO2005023202A3 (en) Tumor suppressor lkb1 kinase directly activates amp-activated kinase
WO2004048526A3 (en) MODULATION OF HIF1α AND HIF2α EXPRESSION
WO2008124083A3 (en) Aurora kinase modulators and method of use
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
WO2011044311A3 (en) Generation, characterization and uses thereof of anti-her 3 antibodies
WO2007044033A3 (en) Therapeutic and diagnostic cloned mhc-unrestricted receptor specific for the muc1 tumor associated antigen
WO2005117968A3 (en) Compositions and methods comprising an egfl7 antagonist for modulating vascular development
WO2006076370A3 (en) Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
WO2010102253A3 (en) Compositions and methods for modulation of cell migration
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
WO2008011484A3 (en) Nicotinic desensitizers and methods of selecting, testing, and using them
WO2004009024A3 (en) Modulation of protein kinase c-iota expression
WO2007140390A3 (en) Method for modulating hair growth
WO2006010142A3 (en) Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
WO2006046134A3 (en) Method of screening by using conformation sensitive peptides
WO2010000851A3 (en) Methods for modulating angiogenesis via dystrophin dp71
WO2006131512A3 (en) Anti-thrombotic agents
EP1441724B8 (en) Methods of increasing endogenous testosterone levels
WO2004051269A3 (en) Ciz1 replication protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2563433

Country of ref document: CA

Ref document number: 2005247332

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007511088

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

ENP Entry into the national phase

Ref document number: 2005247332

Country of ref document: AU

Date of ref document: 20050502

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005247332

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2005780049

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2005780049

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005780049

Country of ref document: EP